Evidence map›Paper›PMID 42614841›Full record

ArticleRSC advances2026

Exploration of non-hydroxamate based quinoline analogues as HDAC8 inhibitors.

N V M Rao Bandaru, Vandana Joshi, Markus Schweipert, Kosana Sai Chaitanya, Dharani Sen, Muzaffar-Ur-Rehman Mohammed, Vivek Sharma, Chandrasekhar Abbineni, Franz-Josef Meyer-Almes, Kondapalli Venkata Gowri Chandra Sekhar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

N V M Rao BandaruDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in.
Vandana JoshiDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India.
Markus SchweipertDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt Haardtring 100 64295 Darmstadt Germany franz-josef.meyer-almes@h-da.de.
Kosana Sai ChaitanyaDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in.
Dharani SenDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India.
Muzaffar-Ur-Rehman MohammedDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani Campus Pilani 333031 Rajasthan India.
Vivek SharmaDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India.ORCID https://orcid.org/0000-0001-7345-4597
Chandrasekhar AbbineniAurigene Oncology Limited 39-40 KIADB Industrial Area Electronic City Phase II, Hosur Road Bangalore 560100 India.
Franz-Josef Meyer-AlmesDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt Haardtring 100 64295 Darmstadt Germany franz-josef.meyer-almes@h-da.de.ORCID https://orcid.org/0000-0002-1001-3249
Kondapalli Venkata Gowri Chandra SekharDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in.ORCID https://orcid.org/0000-0002-2319-8297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase 8 (HDAC8) has emerged as a promising therapeutic target due to its role in epigenetic regulation. In this study, novel non-hydroxamate-based quinoline analogues were designed and explored as HDAC8-selective inhibitors that exhibit nanomolar HDAC8 enzymatic inhibition. Notably, compounds BHC-10 and BHC-13 showed 30 and 42 nM activity, respectively. Compounds exhibiting below 500 nM activity were evaluated for their

Identifiers

PMID42614841
PMCPMC13482965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.